Dersalazine is a dual PAF antagonist and TNFα inhibitor investigated for ulcerative colitis. It demonstrates anti-inflammatory effects in vivo, significantly reducing MPO activity in rat models of reactivated colitis, supporting its research use in inflammatory bowel disease.